生存素在肿瘤中的作用及其耐药机制

doi:10.3760/cma.j.issn.1673-422X.2014.04.001

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (4): 241-243.doi: 10.3760/cma.j.issn.1673-422X.2014.04.001

• 综述 • 下一篇

生存素在肿瘤中的作用及其耐药机制

郑瑛, 陈钦, 张斌, 曹旭晨

300060 天津医科大学肿瘤医院乳腺一科国家肿瘤临床医学研究中心天津市“肿瘤防治”重点实验室乳腺癌防治教育部重点实验室

出版日期:2014-04-08 发布日期:2014-03-17
通讯作者: 曹旭晨，Email: cxc@medmail.com.cn E-mail:cxc@medmail.com.cn
基金资助:
天津市自然科学基金（11JCZDJC28000）

Roles and resistance mechanisms of survivin in tumor

ZHENG Ying, CHEN Qin, ZHANG Bin, CAO Xu-Chen

Tianjin Medical University Cancer Institute and Hospital; National Clinical Research of Cancer; Key Laboratory of Breast Cancer Prevention and Therapy of Tianjin; Key Laboratory of Breast Cancer Prevention and Therapy of the Ministry of Education, Tianjin 300060, China

Online:2014-04-08 Published:2014-03-17
Contact: CAO Xu-Chen E-mail:cxc@medmail.com.cn

摘要/Abstract

摘要： 肿瘤治疗中的耐药问题是影响疾病转归的重要因素，目前已有大量研究发现，生存素（survivin）具有抑制肿瘤细胞凋亡、调控肿瘤细胞周期、促进血管生成、促进肿瘤转移的作用，并可与多种基因及蛋白相互作用，影响肿瘤细胞耐药性。

关键词: 抗药性, 肿瘤, 肿瘤, 多药耐药相关蛋白质类, 生存素

Abstract: Drug resistance in tumor treatment is an important factor that affects disease outcome. A lot of researches show that survivin can inhibit tumor cell apoptosis, regulate cell cycle, promote angiogenesis and tumor metastasis. The interactions among survivin, genes and proteins can influence the drug resistance of tumor cells.

Key words: Drug resistance, neoplasm, Neoplasms, Multidrug resistanceassociated proteins, Survivin

郑瑛, 陈钦, 张斌, 曹旭晨. 生存素在肿瘤中的作用及其耐药机制[J]. 国际肿瘤学杂志, 2014, 41(4): 241-243.

ZHENG Ying, CHEN Qin, ZHANG Bin, CAO Xu-Chen. Roles and resistance mechanisms of survivin in tumor[J]. Journal of International Oncology, 2014, 41(4): 241-243.

参考文献

［1］ Salvesen GS, Duckett CS. IAP proteins: blocking the road to death′s door［J］. Nat Rev Mol Cell Biol, 2002, 3(6): 401410. ［2］ Verdecia MA, Huang H, Dutil E, et al. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement［J］. Nat Struct Biol, 2000, 7(7): 602608. ［3］ Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic celldivision defects and apoptosis induced by interference with survivin function［J］. Nat Cell Biol, 1999, 1(8): 461466. ［4］ Wang L, Yin F, Du Y, et al. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin［J］. Tumour Biol, 2010, 31(3): 225232. ［5］ Wang P, Zhen H, Zhang J, et al. Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo［J］. Mol Carcinog, 2012, 51(7): 586595. ［6］ Li Z, Yang S, Chang T, et al. Antiangiogenesis and anticancer effects of a plasmid expressing both ENDOVEGI151 and small interfering RNA against survivin［J］. Int J Mol Med, 2012, 29(3): 485490. ［7］ Lee J, Choi JH, Joo CK. TGFβ1 regulates cell fate during epithelialmesenchymal transition by upregulating survivin［J］. Cell Death Dis, 2013, 4: e714. ［8］ Ye Q, Cai W, Zheng Y, et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer［J］. Oncogene, 2013, In press. ［9］ Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFRmutant lung cancer by activation of Akt and EGFR［J］. Cancer Res, 2009, 69(8): 32563261. ［10］ Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptoractivating mutations［J］. Cancer Res, 2010, 70(21): 87158725. ［11］ Okamoto K, Okamoto I, Okamoto W, et al. Role of survivin in EGFR inhibitorinduced apoptosis in nonsmall cell lung cancers positive for EGFR mutations［J］. Cancer Res, 2010, 70(24): 1040210410. ［12］ Okamoto K, Okamoto I, Hatashita E, et al. Overcoming erlotinib resistance in EGFR mutationpositive nonsmall cell lung cancer cells by targeting survivin［J］. Mol Cancer Ther, 2012, 11(1): 204213. ［13］ Guha M, Plescia J, Leav I, et al. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing［J］. Cancer Res, 2009, 69(12): 49544958. ［14］ Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps［J］. Nat Rev Cancer, 2010, 10(2): 147156. ［15］ Tsubaki M, Satou T, Itoh T, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrugresistance in multiple myeloma cells［J］. Leuk Res, 2012, 36(10): 13151322. ［16］ Guenova ML, Balatzenko GN, Nikolova VR, et al. An antiapoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase3, cleaved PARPs, Bcl2, Survivin and MDR1 gene［J］. Hematology, 2010, 15(3): 135143. ［17］ He Q, Gao Y, Zhang L, et al. A pHresponsive mesoporous silica nanoparticlesbased multidrug delivery system for overcoming multidrug resistance［J］. Biomaterials, 2011, 32(30): 77117720. ［18］ Cho HJ, Yoon HY, Koo H, et al. Selfassembled nanoparticles based on hyaluronic acidceramide (HACE) and Pluronic(R) for tumortargeted delivery of docetaxel［J］. Biomaterials, 2011, 32(29): 71817190. ［19］ Vergara D, Bellomo C, Zhang X, et al. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer［J］. Nanomedicine, 2012, 8(6): 891899. ［20］ Liu F, Liu S, He S, et al. Survivin transcription is associated with Pglycoprotein/MDR1 overexpression in the multidrug resistance of MCF7 breast cancer cells［J］. Oncol Rep, 2010, 23(5): 14691475. ［21］ Bhattacharyya J, Mihara K, Ohtsubo M, et al. Overexpression of BMI1 correlates with drug resistance in Bcell lymphoma cells through the stabilization of survivin expression［J］. Cancer Sci, 2012, 103(1): 3441. ［22］ OliverasFerraros C, VazquezMartin A, Cufi S, et al. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 geneamplified breast cancer cells with primary resistance to HER1/2targeted therapies［J］. Biochem Biophys Res Commun, 2011, 407(2): 412419. ［23］ Zhu H, Zhang G, Wang Y, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2betacatenin/TCF4survivin pathway in ErbB2overexpressed breast cancer cells［J］. Cancer Sci, 2010, 101(5): 11561162. ［24］ Foster FM, Owens TW, TanianisHughes J, et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer［J］. Breast Cancer Res, 2009, 11(3): R41. ［25］ Wang S, Huang X, Lee CK, et al. Elevated expression of erbB3 confers paclitaxel resistance in erbB2overexpressing breast cancer cells via upregulation of Survivin［J］. Oncogene, 2010, 29(29): 42254236. ［26］ Kelly RJ, Thomas A, Rajan A, et al. A phase Ⅰ/Ⅱ study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced nonsmallcell lung cancer［J］. Ann Oncol, 2013, 24(10): 2601-2606.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

生存素在肿瘤中的作用及其耐药机制

Roles and resistance mechanisms of survivin in tumor

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价